Relief therapeutics « Terug naar discussie overzicht

Relief therapeutics Holding

7.939 Posts, Pagina: « 1 2 3 4 5 6 ... 190 191 192 193 194 195 196 197 198 199 200 ... 393 394 395 396 397 » | Laatste
MisterBlues
1
quote:

MBelegger schreef op 2 november 2020 23:42:


www.linkedin.com/posts/neurorx-pharma...

Als je geen LinkedIn hebt:
Trudi White
Buiten uw netwerk 3rd+
Associate Director of Data Management at NeuroRx, Inc.
2 u geleden
Hi Steve, There will be an interim analysis soon. Hold on!


Op een of andere manier denk ik dat ze het na vandaag, na de verkiezingen willen tillen. Corona-medicijnen zijn per definitie politiek gevoelig en bovendien raakt elke PB nu ondergesneeuwd.

(Het is hinein-interpretatie.) :)
MisterBlues
0
quote:

Zwartgeld schreef op 3 november 2020 09:57:


Is der al bekent wat der aan de hand is???



Not much to worry about...for the real long this is a scenario we ve seen 30 times already. It goes a little bit up on news, goes a little bit down on long periods with no news etc....Till we get an effective approval (EUA or FDA) we will stick between .4 and .5 chf.... There is no magical scenario where this goes differently...
MisterBlues
0
Dit is alles wat je erover kan zeggen:

We had Patient number 102 on 30th September. With the rising number of Covid-Cases during October and one after other phase III trial failing (most recently Regeneron see news last Friday), I would expect that patient recruiting did accelerate over October.

Anybody has news to that ? I was wondering for the following reason:

Even if Aviptadil has strong effect in reducing mortality, 102 patients divided by 2 is 51. According to the study protocol, it was estimated that the mortality could be arround 50 %. However, some aspects improved in the treatment of Covid-19 and maybe also dexamethason had an effect.

What I am trying to say: even if Aviptadil works very well, there is obviously no guarantee that we can make the statistical signficance already with 102 patients, but likely with 144.

I think it is most important that the DMSC allows to continue with this trial as a minimum - if so, that would mean that the DMSC sees at least a trend in favour of Aviptadil and that there is a reasonable chance to hit the required statistical significance.

DMSC could recomment to stop this trial if:
- negative: considerable side effects (I do not expect), or futility (if there is no trend in favour of Aviptadil)
- positive: statistical significance of mortality reduction

It would be neutral-positive if we need to continue, because that would mean, not futile, interim result in favour of Aviptadil, but patients needed to hit statistical signifcance.

Sometimes the DMSC is proposing modifications of the trial - that is still possible. DMSC would only do so, if there were some data in favour of Aviptadil and to adapt the trial to allow the trial to hit statistical significance.
Bert-Jan
1
A cutting from a swiss paper F&W Today

The first results of phase IIb / III with the potential corona drug RLF-100 (Aviptadil) should be known around the end of the year. This is announced by Ram Selvaraju, Chairman of the Board of Directors, at the request of “Finanz und Wirtschaft”. They will provide information about the effectiveness and any side effects.

In August, Selvaraju was still hoping for results in October. Delays in drug trials are not uncommon. The duration depends on how quickly the envisaged number of patients can be recruited. In the case of the Relief study, the targeted number of participants was also increased from 144 to 165.

Continue or cancel the study

Selvaraju expects news soon. "The second interim analysis should follow in the next few days." The monitoring committee, the so-called Data Safety Monitoring Board, will examine the data already available and make a recommendation. This provides an important indication of whether the study is doing well.

If the Board sees a realistic chance that RLF-100 will achieve the goals, it will recommend that the study be continued. It can also request termination, either because it sees no prospect of success or because the data looks so good that an application for approval already makes sense on this basis.

Details would follow later

Relief Therapeutics (RLF 0.446 -3.88%) wants to inform you about the decision of the monitoring committee in any case. However, Selvaraju explains that in the event of dropping out of the study because of outstanding results, the data cannot be communicated immediately. "We would have to withhold the details in the case until they are checked by scientists and published in a specialist journal."

Relief's partner company NeuroRx submitted an application for emergency approval at the end of September. This is because the active ingredient apparently helped patients who had received the anti-inflammatory drug as part of a so-called compassionate use program. The remaining treatment options had been exhausted, and the patients were so seriously ill that they could not be included in a regular study. The 21 people treated with RLF-100 had a three times higher chance of survival than the 30 who received standard therapy.
DeZwarteRidder
0
quote:

Beso schreef op 3 november 2020 11:38:


iemand weer aan het dumpen? Hoog volume en RT 0,419

Ongetwijfeld GEM.....!!!
LuckyLoeke
1
quote:

Driessen schreef op 3 november 2020 11:59:


iemand enig idee wat er gaande is? gewoon winstnemers?



Een paar verkooporders tussen de 600k en 1.2mil van mensen die hun verkoop limiet hebben bereikt of zwakke handjes hebben tijdens deze koersdaling die al zo vaak is voorgekomen.
See for yourself: www.swissquote.ch/sqi_atools/Analysis...

De meesten zitten vanaf augustus erin om dan 2-3 maanden te wachten en tegen een lagere koers te verkopen??!! haha
Ik blijf toch lekker zitten zoals de meesten.

ps: F*** DZR en en zijn GEM waarschuwingen. zolang hij t blijft roepen zal je 1 keer van de 10000 keer wel eens juist zijn, maar dat is nog niet voor nu.
LuckyLoeke
0
DeZwarteRidder
1
quote:

LuckyLoeke schreef op 3 november 2020 12:14:


[...]Een paar verkooporders tussen de 600k en 1.2mil van mensen die hun verkoop limiet hebben bereikt of zwakke handjes hebben tijdens deze koersdaling die al zo vaak is voorgekomen.
See for yourself: www.swissquote.ch/sqi_atools/Analysis...

De meesten zitten vanaf augustus erin om dan 2-3 maanden te wachten en tegen een lagere koers te verkopen??!! haha
Ik blijf toch lekker zitten zoals de meesten.

ps: F*** DZR en en zijn GEM waarschuwingen. zolang hij t blijft roepen zal je 1 keer van de 10000 keer wel eens juist zijn, maar dat is nog niet voor nu.

Wat betekent F*** ???
Florissant
0
Beso
0
en weer hard omhoog van 0,36 naar 0,419. Kan ook voorkennis zijn voorlopend op goed nieuws en pogen kleine beleggers in paniek te doen verkopen om goedkoop bij te kunnen tanken. Ik blijf zitten
Kleintje66
1
quote:

Driessen schreef op 3 november 2020 11:59:


iemand enig idee wat er gaande is? gewoon winstnemers?

Gemelde vertraging. Was al te verwachten. Toch weer wat bijgekocht, ik kan het niet laten met die enorme drop.
Stier de Beer
0
Veert al weer op. Doe er je voordeel mee.

De RLF-100 resultaten tot nu toe spreken voor zich
Belegger 86
1
7.939 Posts, Pagina: « 1 2 3 4 5 6 ... 190 191 192 193 194 195 196 197 198 199 200 ... 393 394 395 396 397 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 12 mei 2021 17:31
Koers 0,186
Verschil +0,007 (+3,92%)
Hoog 0,188
Laag 0,177
Volume 8.774.096
Volume gemiddeld 18.340.237
Volume gisteren 23.501.594

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront